1.71
Schlusskurs vom Vortag:
$1.76
Offen:
$1.77
24-Stunden-Volumen:
977.12K
Relative Volume:
0.56
Marktkapitalisierung:
$393.86M
Einnahmen:
$8.95M
Nettoeinkommen (Verlust:
$-21.49M
KGV:
-14.25
EPS:
-0.12
Netto-Cashflow:
$-29.24M
1W Leistung:
+4.27%
1M Leistung:
-1.72%
6M Leistung:
+61.32%
1J Leistung:
+221.31%
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Firmenname
Lineage Cell Therapeutics Inc
Sektor
Branche
Telefon
510-871-4188
Adresse
2173 Salk Avenue, Suite 200, Carlsbad, CA
Vergleichen Sie LCTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics Inc
|
1.71 | 405.38M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-20 | Eingeleitet | Craig Hallum | Buy |
| 2022-11-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-08-19 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-03-31 | Eingeleitet | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten
What dividend safety score for Lineage Cell Therapeutics Inc. stock2025 Geopolitical Influence & Safe Entry Point Alerts - ulpravda.ru
Aug Outlook: Is Lineage Cell Therapeutics Inc. stock among top earnings playsJuly 2025 Earnings & Comprehensive Market Scan Insights - ulpravda.ru
Institution Moves: How Lineage Cell Therapeutics Inc. stock trades during market volatility2025 Stock Rankings & Daily Stock Trend Reports - ulpravda.ru
Why Lineage Cell Therapeutics Inc. stock is a must watch in 2025July 2025 Breakouts & Safe Capital Growth Plans - ulpravda.ru
Is Lineage Cell Therapeutics Inc. stock among top earnings playsJuly 2025 Earnings & Comprehensive Market Scan Insights - ulpravda.ru
What dividend safety rating applies to Lineage Cell Therapeutics Inc. stock2025 Technical Overview & Target Return Focused Picks - ulpravda.ru
Can Lineage Cell Therapeutics Inc. stock resist sector downturnsEarnings Trend Report & Precise Swing Trade Alerts - ulpravda.ru
Will Lineage Cell Therapeutics Inc. stock deliver long term returnsTrade Signal Summary & Community Supported Trade Ideas - ulpravda.ru
Earnings Miss: Can Lineage Cell Therapeutics Inc. stock resist sector downturnsJuly 2025 Gainers & Reliable Entry Point Trade Alerts - ulpravda.ru
CEO Change: What dividend safety rating applies to Lineage Cell Therapeutics Inc. stock2025 AllTime Highs & Daily Stock Trend Reports - ulpravda.ru
D. Boral Capital Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - MSN
2026 world cup injury update tips: Will Lineage Cell Therapeutics Inc. stock benefit from sector rotation2026 world cup usa national team group stage goalkeepers transition play group prediction guide - ulpravda.ru
Lineage Cell Therapeutics (LCTX) Advances Stem Cell Collaboratio - GuruFocus
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Business Wire
Lineage Cell Therapeutics highlights 2025 achievements in cell therapy By Investing.com - Investing.com Nigeria
Lineage Cell Therapeutics Issues Letter to Stockholders - pharmiweb.com
Lineage Cell Therapeutics highlights 2025 achievements in cell therapy - Investing.com
Is Lineage Cell Therapeutics Inc a good long term investmentInsider Trading Compliance & Free Stay Ahead With Picks - earlytimes.in
Cell Therapy Manufacturing Market Forecast Through 2032 - openPR.com
Lineage Cell Therapeutics Reports Q3 2025 Results - MSN
Lineage Cell Therapeutics: Progress Amid Financial Challenges - MSN
EBIT per share of Lineage Cell Therapeutics, Inc. – DUS:BT3 - TradingView — Track All Markets
How Low Can Lineage Cell Therapeutics Stock Really Go? - Trefis
Q3 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Is Lineage Cell Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Chart Watch & Safe Capital Allocation Plans - Улправда
Is Lineage Cell Therapeutics Inc. stock trading at a premium valuation2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Aug Wrap: Can Lineage Cell Therapeutics Inc. stock surprise with earnings upsideWeekly Gains Report & Daily Momentum Trading Reports - Улправда
Lineage Cell Therapeutics (LCTX) officer reports RSU vesting and tax share withholding - Stock Titan
Can Lineage Cell Therapeutics Inc. stock surprise with earnings upside2025 Dividend Review & Real-Time Buy Signal Notifications - Улправда
Will Lineage Cell Therapeutics Inc. stock outperform foreign stocksPortfolio Value Report & Stepwise Entry/Exit Trade Alerts - DonanımHaber
Lineage Cell Therapeutics (LCTX) CEO discloses RSU vesting and tax share withholding - Stock Titan
Buybacks Report: How rising interest rates impact Lineage Cell Therapeutics Inc. stockTreasury Yields & Daily Chart Pattern Signals - Улправда
LCTX’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading 4.7% HigherShould You Buy? - MarketBeat
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading 4.7% Higher – Should You Buy? - Defense World
Aug Shorts: Can Lineage Cell Therapeutics Inc stock withstand sector downturnsPortfolio Gains Report & AI Powered Trade Plan Recommendations - moha.gov.vn
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy - PR Newswire
New Horizons in Cancer Stem Cells Market Exclusive Report with - openPR.com
You might want to take a look at Lineage Cell Therapeutics Inc (LCTX) now - setenews.com
Lineage Cell Therapeutics Q3 2025 Earnings Preview - MSN
Model VAC2Immuno-Oncology for Non-Small Cell Lung Cancer (NSCLC) - Environmental XPRT
How Lineage Cell Therapeutics Inc. stock valuation compares with sector2025 Historical Comparison & Smart Investment Allocation Tips - Newser
What insider trading reveals about Lineage Cell Therapeutics Inc. stockSell Signal & Daily Growth Stock Tips - Newser
Is Lineage Cell Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
How Lineage Cell Therapeutics Inc. stock performs during market turbulence2025 Top Decliners & Safe Swing Trade Setups - Newser
How currency fluctuations impact Lineage Cell Therapeutics Inc. stockPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
Is Lineage Cell Therapeutics Inc. stock safe for risk averse investorsCEO Change & Daily Stock Trend Reports - Newser
Is Lineage Cell Therapeutics Inc. stock attractive for growth ETFsPortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock cheap by valuation metricsJuly 2025 Review & Entry Point Confirmation Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock expanding market penetrationMarket Growth Report & Technical Entry and Exit Alerts - Newser
Will Lineage Cell Therapeutics Inc. stock beat international competitionJuly 2025 Action & Precise Swing Trade Entry Alerts - Newser
Finanzdaten der Lineage Cell Therapeutics Inc-Aktie (LCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):